



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: April 4, 2008

To: Primary Clinical Research Associates

From: Sara Braun
Protocol Development Coordinator

Re: N0682, A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab in Previously Untreated Follicular B-cell Non-Hodgkin's Lymphoma

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

This study was approved by the National Cancer Institute on March 13, 2007.

Please note that for this study it will not be feasible to send a “starter” supply of study drug to sites upon request as is our normal practice. For several reasons, we will need to restrict drug shipments to those sites with potential activity (i.e. ones who have identified a potential study patient).

Before ordering study drug, please review the storage requirements in the Drug Information (Section 15.0) of the protocol to be sure you have adequate storage available at your institution.

If you have any questions, please feel free to contact me.

Enclosure